Company News
12 Jul 2024
In this Q&A with Paul Kase, Lumos’ SVP, Commercial Operations, Paul outlines how Lumos is working in partnership with Henry Schein to access key global markets, and the imminent availability of FebriDx® to Australian healthcare practitioners as Australia enters its peak flu season.
Take a look:
A few more pieces along the same thread. See the full index for everything.
COMPANY NEWS
1 min read
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
COMPANY NEWS
2 min read
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
COMPANY NEWS
1 min read
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...